These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12942728)

  • 1. [Spasmex treatment of patients with hyperactive urinary bladder].
    Pushkar' DIu; Shchaveleva OB
    Urologiia; 2003; (4):46-9. PubMed ID: 12942728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial.
    Malone-Lee J; Shaffu B; Anand C; Powell C
    J Urol; 2001 May; 165(5):1452-6. PubMed ID: 11342895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder].
    Deng YJ; Ma G; Guo YF; Ge Z; Lu RG; Wang LX; Zhu HB; Chen CJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jan; 13(1):26-8. PubMed ID: 21251382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Overactive bladder. New anticholinergic drug controls urinary urge].
    MMW Fortschr Med; 2004 Jul; 146(27-28):51. PubMed ID: 15526670
    [No Abstract]   [Full Text] [Related]  

  • 5. [Trospium chloride (spasmex) in the treatment of lower urinary tract symptoms in patients with neurogenic hyperactive urinary bladder caused by vertebrogenic lesions].
    Mazo EB; Babanina GA
    Urologiia; 2007; (3):15-9. PubMed ID: 17722614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Urinary incontinence--treatment].
    Hader C; Welz-Barth A; Keller T
    Dtsch Med Wochenschr; 2003 Apr; 128(14):750-2. PubMed ID: 12673531
    [No Abstract]   [Full Text] [Related]  

  • 7. Contemporary treatment options for overactive bladder.
    Taylor PH; Sussman DO
    JAAPA; 2005 Nov; Suppl():3-13; quiz 14-5. PubMed ID: 16315503
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity.
    Ethans KD; Nance PW; Bard RJ; Casey AR; Schryvers OI
    J Spinal Cord Med; 2004; 27(3):214-8. PubMed ID: 15478523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage.
    Horstmann M; Schaefer T; Aguilar Y; Stenzl A; Sievert KD
    Neurourol Urodyn; 2006; 25(5):441-5. PubMed ID: 16847942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Trospium chloride in the treatment of idiopathic and neurogenic detrusor overactivity].
    Mazo EB; Krivoborodov GG; Shkol'nikov ME; Babanina GA; Kozyrev SV; Korshunov ES
    Urologiia; 2005; (4):56-9. PubMed ID: 16158750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trospium chloride for the treatment of overactive bladder with urge incontinence.
    Singh-Franco D; Machado C; Tuteja S; Zapantis A
    Clin Ther; 2005 May; 27(5):511-30. PubMed ID: 15978301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detrol LA and Diropan XL for overactive bladder.
    Med Lett Drugs Ther; 2001 Apr; 43(1101):28. PubMed ID: 11283473
    [No Abstract]   [Full Text] [Related]  

  • 13. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects.
    Amend B; Hennenlotter J; Schäfer T; Horstmann M; Stenzl A; Sievert KD
    Eur Urol; 2008 May; 53(5):1021-8. PubMed ID: 18243516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG; Al-Buheissi S
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [M-cholinolytic spasmex and its role in preoperative preparation of patients with urine incontinence].
    Danilov VV; Danilova TI
    Urologiia; 2007; (1):33-6. PubMed ID: 17471995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Schaefer W
    J Urol; 2006 Nov; 176(5):2311-2; author reply 2312-3. PubMed ID: 17070326
    [No Abstract]   [Full Text] [Related]  

  • 19. Medical treatment of overactive bladder.
    Rackley R; Wein A; Nelson D
    Mayo Clin Proc; 2001 Nov; 76(11):1179-80. PubMed ID: 11702910
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome.
    Hsiao SM; Chang TC; Wu WY; Chen CH; Yu HJ; Lin HH
    J Obstet Gynaecol Res; 2011 Aug; 37(8):1084-91. PubMed ID: 21501328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.